E-LIB Suche - Ergebnisse für: Paneesha, S.

1

CAR T treatment access and outcomes in patients with large ..:

Dragoi, D. ; Cusworth, S. ; Amrith, M....
Hematological Oncology. 41 (2023) S2 - p. 452-453 , 2023

Link: https://doi.org/10.1002/..

2

S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS ..:

Hillmen, P. ; Pitchford, A. ; Bloor, A....
HemaSphere. 6 (2022) - p. 46-47 , 2022

Link: https://doi.org/10.1097/..

3

P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MA..:

Tivey, A. ; Shotton, R. ; Eyre, T. A....
HemaSphere. 6 (2022) - p. 1031-1032 , 2022

Link: https://doi.org/10.1097/..

4

P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDO..:

Sehn, L. H. ; Hübel, K. ; Luminari, S....
HemaSphere. 6 (2022) - p. 993-994 , 2022

Link: https://doi.org/10.1097/..

5

INMIND: A PHASE 3 STUDY OF TAFASITAMAB + LENALIDOMIDE AND R..:

Hübel, K. ; Scholz, C. W. ; Luminari, S....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

6

Antibody responses after first and second Covid-19 vaccinat..:

Parry, H. ; McIlroy, G. ; Bruton, R....
Blood Cancer Journal. 11 (2021) 7 - p. , 2021

Link: https://doi.org/10.1038/..

7

Covid-19 infection in therapy-naive patients with B-cell ch..:

Paneesha, S. ; Pratt, G. ; Parry, H..
Leukemia Research. 93 (2020) - p. 106366 , 2020

Link: https://doi.org/10.1016/..

8

Favourable outcomes for high-risk diffuse large B-cell lymp..:

McMillan, A.K. ; Phillips, E.H. ; Kirkwood, A.A....
Annals of Oncology. 31 (2020) 9 - p. 1251-1259 , 2020

Link: https://doi.org/10.1016/..

9

BRIEF CO‐ADMINISTRATION OF IDELALISIB MAY IMPROVE THE LONG‐..:

Pettitt, A. ; Kalakonda, N. ; Cicconi, S....
Hematological Oncology. 37 (2019) S2 - p. 217-218 , 2019

Link: https://doi.org/10.1002/..

10

NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET‐GUIDED, RESP..:

Pettitt, A.R. ; Barrington, S. ; Kalakonda, N....
Hematological Oncology. 37 (2019) S2 - p. 67-68 , 2019

Link: https://doi.org/10.1002/..

11

Graft-versus-leukaemia effect post fludarabine, melphalan a..:

Kanellopoulos, A. ; Kaparou, M. ; Xenou, E....
Bone Marrow Transplantation. 53 (2018) 12 - p. 1518-1521 , 2018

Link: https://doi.org/10.1038/..

12

EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EI..:

Pettitt, A.R. ; Kalakonda, N. ; Polydoros, F....
Hematological Oncology. 35 (2017) S2 - p. 88-89 , 2017

Link: https://doi.org/10.1002/..

13

Treatment outcomes using involved field and involved site r..:

Jayalathike, D.M. ; Stevens, A. ; Paneesha, S....
Hematological Oncology. 35 (2017) S2 - p. 333-333 , 2017

Link: https://doi.org/10.1002/..

14

Post-transplant T cell chimerism predicts graft versus host..:

Nikolousis, E. ; Robinson, S. ; Nagra, S....
Leukemia Research. 37 (2013) 5 - p. 561-565 , 2013

Link: https://doi.org/10.1016/..

15

Elevated D-dimers are also a marker of underlying malignanc..:

Knowlson, L ; Bacchu, S ; Paneesha, S...
Journal of Clinical Pathology. 63 (2010) 9 - p. 818-822 , 2010

Link: https://doi.org/10.1136/..